Current Report Filing (8-k)
November 01 2017 - 9:48AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION
13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of
Earliest Event Reported):
November
1, 2017
GERON
CORPORATION
(Exact name of
registrant as specified in its charter)
Delaware
|
0-20859
|
75-2287752
|
(State or
other jurisdiction of
|
(Commission
File Number)
|
(IRS
Employer
|
incorporation)
|
|
Identification No.)
|
149 COMMONWEALTH DRIVE,
SUITE 2070
MENLO PARK, CALIFORNIA 94025
(Address of principal executive offices, including
zip code)
(650)
473-7700
(Registrant's
telephone number, including area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On November 1, 2017, Geron
Corporation issued a press release entitled Geron Announces Presentations at American
Society of Hematology Annual Meeting which describes the abstracts related to
the telomerase inhibitor imetelstat that have been accepted for presentation at
the 59th American Society of Hematology (ASH) Annual Meeting and Exposition to
be held in Atlanta, Georgia from December 9-12, 2017. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference. In addition, a copy of the abstract entitled
Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS
Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA)
(IMerge) is attached as Exhibit 99.2 to this Current Report on Form 8-K and is
incorporated herein by reference.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
1
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GERON
CORPORATION
|
|
Date:
November 1, 2017
|
By:
|
/s/ Stephen N. Rosenfield
|
|
|
Stephen N.
Rosenfield
|
|
|
Executive
Vice President, General
|
|
|
Counsel and
Corporate Secretary
|
2
Geron (NASDAQ:GERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2023 to Apr 2024